Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Up 601.2% in February

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a significant increase in short interest in February. As of February 27th, there was short interest totaling 1,274,209 shares, an increase of 601.2% from the February 12th total of 181,710 shares. Based on an average daily trading volume, of 2,687,153 shares, the days-to-cover ratio is currently 0.5 days. Approximately 9.2% of the company’s stock are sold short. Approximately 9.2% of the company’s stock are sold short. Based on an average daily trading volume, of 2,687,153 shares, the days-to-cover ratio is currently 0.5 days.

Kairos Pharma Stock Performance

NYSEAMERICAN KAPA traded up $0.01 during trading on Tuesday, reaching $0.64. 180,499 shares of the company’s stock were exchanged, compared to its average volume of 1,315,610. Kairos Pharma has a 1 year low of $0.40 and a 1 year high of $2.11. The stock has a market cap of $13.32 million, a P/E ratio of -2.06 and a beta of 2.28. The company has a 50 day moving average price of $0.70 and a two-hundred day moving average price of $0.94.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Kairos Pharma in a research note on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $8.33.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in shares of Kairos Pharma in the 2nd quarter valued at $44,000. Two Sigma Investments LP purchased a new stake in Kairos Pharma in the third quarter valued at $54,000. Finally, FNY Investment Advisers LLC acquired a new position in Kairos Pharma in the third quarter valued at $27,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.